Passage BIO (PASG) Depreciation & Amortization (CF) (2019 - 2026)
Passage BIO (PASG) posted quarterly Depreciation & Amortization (CF) of $100000.0 for Q1 2026, down 50.0% year-over-year from $200000.0 in Q1 2025, and down 32.89% quarter-over-quarter from $149000.0 in Q4 2025.
Passage BIO (PASG) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Passage BIO's Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 50.0% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $649000.0 (down 73.84% YoY), while the FY2025 annual figure was $700000.0, down 77.28% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $100000.0, down from $149000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.0 million in Q4 2022, with the low at $100000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $800000.0 (2023), against an average of $672705.9.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 343.35% in 2022, then tumbled 78.12% in 2025.
- Passage BIO's Depreciation & Amortization (CF) stood at $1.0 million in 2022, then slipped by 20.0% to $800000.0 in 2023, then slipped by 14.88% to $681000.0 in 2024, then sank by 78.12% to $149000.0 in 2025, then slumped by 32.89% to $100000.0 in 2026.
- Business Quant data shows PASG's Depreciation & Amortization (CF) at $100000.0 in Q1 2026, $149000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | 71,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71,000.00 |
| Jun 30, 2026 | 71,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 149,000.00 |
| Dec 31, 2025 | 149,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 681,000.00 |
| Dec 31, 2024 | 681,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 806,000.00 |
| Mar 31, 2024 | 806,000.00 |